- Huntington's Cutbacks Lead to Retiree's Suicide
- Saturday Tsubasacon Cosplay Contest and Skits
- UPDATED: Large Selection New Tsubasacon Mascarade, Winners, Skits, Cosplaying IMAGES
- FLASHBACK IMAGE COLLECTION: The Making of We Are Marshall In Huntington
- BREAKING: Oscar Mishap... "Moonlight," Wins Best Picture After "La La Land" Crew on Stage
- Piketon Diffusion Plant Clean Up Comment Period Extended
- Drug Distributors Penalized For Turning Blind Eye In Opioid Epidemic
- Huntington City Council Agenda Announced
- Elsa from Frozen Made a Cameo Appearance Leading Huntington Parade, Visits Eastgate Mall Saturday in Cincy IMAGES
- One Nation, Under Sedation: Medicare Paid for Nearly 40 Million Tranquilizer Prescriptions in 2013
Biomedical sciences researcher to present results of clinical trials on personalized chemotherapy
Thursday, June 12, 2014 - 03:21 Updated 2 years ago Special to HNN Provided by Marshall University
He will be discussing the results of clinical trials conducted at the Edwards Comprehensive Cancer Center. The studies tested ChemoID, a cell culture method he developed with colleague Dr. Jagan Valluri to measure the sensitivity of patients' tumors to chemotherapy treatment for lung, brain/spine and breast cancer.
He says more evaluation of the technology is needed, but preliminary tests on a small number of patients found ChemoID 100 percent accurate in predicting which drug is more effective in treating patients affected by brain cancer if the tumor-initiating cancer stem cells were evaluated.
"Oncologists every day face many challenges in determining the best course of therapy for an individual cancer patient," says Claudio. "The basic problem is that patients with similar diagnoses don't always respond to the same chemotherapy. This technology we have developed could help physicians select the appropriate chemotherapy for an individual patient giving them an edge in the fight against cancer."
He says the good news for cancer patients is that ChemoID may make possible personalized treatment by predicting the most effective drug combination to successfully target that specific patient's cancer increasing the chance the drugs will work and perhaps reducing side effects by helping the patient avoid unnecessary drugs.
In addition to presenting his own research at the conference, Claudio will be moderating a session, "Advances in Oncology and Anticancer Research. Cancer Pathology."
Summaries of the research presented at the meeting will be published in the journal Frontiers in Bioscience.